NEW YORK (GenomeWeb News) — The Burnham Institute for Medical Research has inked an assay-development and license agreement with Johnson & Johnson Pharmaceutical Research and Development that will give the drug maker access to some of Burnham's high-throughput screening technologies to study drug targets for inflammatory diseases, Burnham said on Monday.

Burnham CEO John Reed said in a statement that he thinks the collaboration, which is the institute's first with a large pharma, "will foster the discovery of drug products with real clinical potential."

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.